In fact, a p19 peptide-based vaccine for the treatment of colitis has been developed by a research group (Guan et al., 2013) and used in an experimental mouse TNBS model, which showed that the vaccine inhibited IL-23 production and reduced colitis activity, suggesting that IL-23 could be used as a target for the treatment of IBD. Here, IL37 is linked to inflammatory bowel disease.